Upadacitinib is an oral, selective, and reversible JAK inhibitor. In 2 recent phase 3 trials, upadacitinib has demonstrated to outperform placebo after 8 weeks of induction therapy in patients with moderately to severely active UC. Rapid symptom control is important for UC patients, since their quality of life is reduced by gastrointestinal symptoms, such as abdominal pain, bowel urgency, and diarrhoea. Therefore, the current study investigated whether upadacitinib is more efficacious than placebo after only 2 weeks of therapy [1]. Patients were randomised 2:1 to upadacitinib (45 mg, once daily) or placebo in both the U-ACHIEVE (NCT02819635) and U-ACCOMPLISH trial (NCT03653026). Clinical remission, clinical response, stool frequency score, and rectal bleeding score were the clinical endpoints of this post-hoc analysis of these 2 trials. Dr Edward Loftus Jr (Mayo Clinic College of Medicine, MN, USA) presented the results.
In both trials, all clinical endpoints demonstrated significant patient benefits for upadacitinib over placebo after 2 weeks of therapy. In the U-ACHIEVE trial, the proportion of patients that had reached the clinical endpoints in the upadacitinib arm was 15% to 40% larger than for the placebo arm, depending on the observed endpoint. The U-ACCOMPLISH trial showed even more benefits of upadacitinib over placebo, with differences on clinical endpoints ranging from 25% to 40%. In addition, inflammatory markers faecal calprotectin and high-sensitivity C-reactive protein were significantly lower after 2 weeks among upadacitinib receivers compared with placebo receivers.
- Loftus Jr EV, et al. Rapidity of symptom control with upadacitinib induction therapy in patients with moderately to severely active ulcerative colitis: results from two randomized phase 3 studies. OP043, UEG Week 2021 Virtual Congress, 03–05 October.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Filgotinib demonstrates promising results for various lines of therapy in UC Next Article
Upadacitinib outperforms placebo in UC patients with inadequate response to biologics »
« Filgotinib demonstrates promising results for various lines of therapy in UC Next Article
Upadacitinib outperforms placebo in UC patients with inadequate response to biologics »
Table of Contents: UEGW 2021
Featured articles
Updates in Biologics
Risankizumab meets primary endpoints in maintenance study for CD patients
Ustekinumab treat-to-target strategy offers long-term alternative for standard-of-care in CD
Long-term efficacy data of dupilumab for eosinophilic oesophagitis
Updates in Small Molecules
Upadacitinib efficacious and safe as maintenance therapy for UC
Upadacitinib outperforms placebo in UC patients with inadequate response to biologics
Rapid symptom control for UC patients on upadacitinib
Filgotinib demonstrates promising results for various lines of therapy in UC
Filgotinib demonstrates long-term corticosteroid-sparing effects in UC
Long-term benefits of tofacitinib for substantial proportion of UC patients
Ritlecitinib and brepocitinib are promising JAK inhibitors for UC
First pharmacological therapy with clear efficacy in coeliac disease patients
Endoscopy
Motorised spiral enteroscopy safe in real-life and in patients with altered anatomy
Novel tool can reliably exclude submucosal invasion in colorectal polyps
Other Updates
Serologic response to COVID-19 mRNA vaccine reduced in IBD patients on anti-TNFα
Serious adverse events put a stop to ASTIClite trial for CD
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy